Quantitative histology of myeloma‐induced bone changes
- 1 December 1982
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 52 (4) , 601-610
- https://doi.org/10.1111/j.1365-2141.1982.tb03936.x
Abstract
Summary. In order to quantify bone changes which occur in multiple myeloma, undecalcified transiliac bone biopsies from 118 myelomatous patients were analysed by histomorphometric methods. Osteoclastic resorption surfaces were increased compared with controls, and the number of osteoclasts/mm2 of bone section was significantly greater in the areas massively invaded by plasma cells than in less invaded areas. The osteoid surfaces were also increased and the percentage of trabeculae that exhibited tetracycline labelling was also greater, indicating increased formation surfaces. However, reduced thickness of the osteoid seams and a low calcification rate, measured after tetracycline double labelling, suggests a reduced activity for each osteoblast. The mean trabecular bone volume was not reduced as compared with controls, but the biopsies showed a heterogeneous distribution of osteolytic and osteosclerotic areas. In the invaded areas, no major histomorphometric difference was found between patients receiving chemotherapy and untreated patients, demonstrating that if usual chemotherapies reduce the tumour mass, they do not improve histological bone lesions in areas still invaded by plasma cells.This publication has 16 references indexed in Scilit:
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980
- New Diphosphonates to Block Bone ResorptionNew England Journal of Medicine, 1980
- Plasma cell neoplasia with osteosclerotic lesions. A study of five cases and a review of the literatureArchives of internal medicine (1960), 1979
- INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosisMetabolic Bone Disease and Related Research, 1979
- Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.The Journal of Experimental Medicine, 1979
- Effect of osteoclast activating factor from human leukocytes on bone metabolism.Journal of Clinical Investigation, 1975
- Evidence for the Secretion of an Osteoclast Stimulating Factor in MyelomaNew England Journal of Medicine, 1974
- Physiological senile involution and pathological rarefaction of boneClinics in Endocrinology and Metabolism, 1973
- Tetracycline-based histological analysis of bone remodelingCalcified Tissue International, 1969